Home BeiGene's First-in-Class AKT1 Selective Inhibitor TER-2013 IND Application Accepted by China's NMPA

BeiGene's First-in-Class AKT1 Selective Inhibitor TER-2013 IND Application Accepted by China's NMPA

Nov 21, 2026 08:00 CST Updated 08:00
BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Terremoto Biosciences

Covalent Drug Developer

▎Armstrong

On November 18, 2026, the clinical trial application for BeOne’s TER-2013 tablets was accepted by the NMPA.

Image

TER-2013 is the world’s first selective AKT1 inhibitor, developed by Terremoto Biosciences, with its global Phase 1/2 clinical trial having been initiated in September 2025.

Image

In April this year, Terremoto Biosciences announced the completion of a $108 million Series C financing round, with BeOne participating in this round of funding.

Image
Image

Terremoto Biosciences, founded in 2022, focuses on the development of lysine-targeted covalent inhibitors. Previous covalent drugs have mostly targeted cysteine residues due to their high reactivity; however, the scarcity of cysteine in proteins limits the number of available targets. In contrast, lysine is more abundant in proteins but exhibits inherently low reactivity. Terremoto Biosciences has established a technological platform for lysine-targeted covalent inhibitors, upon which it has built its research and development pipeline.

Image

In November 2024, Terremoto Biosciences published a research article on AKT1-selective inhibitors in the journal Nature.AKT1 as a Disease-Driver Gene,Whereas the AKT2 isoform is associated with rash、directly associated with severe adverse reactions such as dysregulation of glucose homeostasis. However, due to their high sequence homology, traditional methods have failed to identify selective inhibitors. Terremoto Biosciences’ lysine-targeted covalent inhibitor approach specifically addresses this challenge, leading to the development of a selective AKT1 inhibitor.

Image
Image

In in vivo tumor models, this AKT1-selective inhibitor demonstrates superior antitumor activity without causing side effects such as hyperglycemia.

Image

Summary

Based on the filing details, BeOne may have entered into a pipeline collaboration with Terremoto Biosciences during its investment process, acquiring the Chinese rights to Terremoto’s AKT1-selective inhibitor; specific terms are subject to official announcements.

Image

Armstrong Technology Comprehensive Review Series